Novo Nordisk A/S (NYSE:NVO) Receives $145.00 Consensus PT from Brokerages

Novo Nordisk A/S (NYSE:NVO – Get Rating) has been given a consensus rating of “Moderate Buy” by the nine ratings firms that are presently covering the stock, Marketbeat.com reports. One analyst has rated the stock with a sell recommendation, five have issued a buy recommendation and one has issued a strong buy recommendation on the company. The average 12 month price target among analysts that have issued ratings on the stock in the last year is $145.00.

NVO has been the topic of several research analyst reports. Credit Suisse Group raised Novo Nordisk A/S from a “neutral” rating to an “outperform” rating in a research note on Thursday, April 13th. StockNews.com assumed coverage on Novo Nordisk A/S in a research note on Thursday, May 18th. They issued a “strong-buy” rating on the stock.

Institutional Trading of Novo Nordisk A/S

Several hedge funds and other institutional investors have recently modified their holdings of NVO. Delta Financial Group Inc. grew its stake in shares of Novo Nordisk A/S by 0.5% during the first quarter. Delta Financial Group Inc. now owns 12,557 shares of the company’s stock worth $1,998,000 after buying an additional 61 shares during the last quarter. Financial Management Professionals Inc. grew its stake in shares of Novo Nordisk A/S by 27.5% in the first quarter. Financial Management Professionals Inc. now owns 301 shares of the company’s stock worth $48,000 after purchasing an additional 65 shares during the last quarter. Pinnacle Wealth Planning Services Inc. grew its stake in shares of Novo Nordisk A/S by 0.8% in the first quarter. Pinnacle Wealth Planning Services Inc. now owns 8,970 shares of the company’s stock worth $1,427,000 after purchasing an additional 69 shares during the last quarter. Venture Visionary Partners LLC grew its stake in shares of Novo Nordisk A/S by 4.9% in the first quarter. Venture Visionary Partners LLC now owns 1,551 shares of the company’s stock worth $247,000 after purchasing an additional 73 shares during the last quarter. Finally, MGO One Seven LLC grew its stake in shares of Novo Nordisk A/S by 1.0% in the fourth quarter. MGO One Seven LLC now owns 7,886 shares of the company’s stock worth $1,067,000 after purchasing an additional 75 shares during the last quarter. Institutional investors and hedge funds own 6.09% of the company’s stock.

Novo Nordisk A/S Stock Performance

Shares of Novo Nordisk A/S stock opened at $163.48 on Friday. The company has a market capitalization of $369.95 billion, a PE ratio of 43.02, a PEG ratio of 1.66 and a beta of 0.48. Novo Nordisk A/S has a 12 month low of $95.02 and a 12 month high of $172.97. The company has a current ratio of 0.86, a quick ratio of 0.67 and a debt-to-equity ratio of 0.30. The stock’s fifty day simple moving average is $161.72 and its 200 day simple moving average is $143.13.

Novo Nordisk A/S Company Profile

(Get Rating)

Novo Nordisk A/S is a global healthcare company, which engages in the the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Biopharm segments. The Diabetes and Obesity Care segment includes insulin, GLP-1 and related delivery systems, oral antidiabetic products (OAD), obesity, and other serious chronic diseases.